APA (7th ed.) Citation

V, C., PJ, W., DT, M., J, C., C, B., A, C., . . . J, F. (2026). Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study. Clinical pharmacology in drug development, 15(2), e70031. https://doi.org/10.1002/cpdd.70031

Chicago Style (17th ed.) Citation

V, Chow, Winkle PJ, Mytych DT, Cao J, Barragan C, Colbert A, Gupta S, Radziszewski W, and Franklin J. "Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study." Clinical Pharmacology in Drug Development 15, no. 2 (2026): e70031. https://doi.org/10.1002/cpdd.70031.

MLA (9th ed.) Citation

V, Chow, et al. "Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study." Clinical Pharmacology in Drug Development, vol. 15, no. 2, 2026, p. e70031, https://doi.org/10.1002/cpdd.70031.